Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.
Andersson M, Alvarez-Cermeño J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Grønning M, et al. Andersson M, et al. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902. doi: 10.1136/jnnp.57.8.897. J Neurol Neurosurg Psychiatry. 1994. PMID: 8057110 Free PMC article. Review.
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana JE, Álvarez-Cermeño JC, Casanova Estruch B, Izquierdo Ayuso G, Ortiz Castillo R, Rodríguez-Antigüedad A, Calles Hernández C; en nombre del Grupo de Estudio LEMVIDA. Meca-Lallana JE, et al. Among authors: alvarez cermeno jc. Neurologia (Engl Ed). 2024 Jun;39(5):383-391. doi: 10.1016/j.nrleng.2021.06.006. Epub 2023 Apr 26. Neurologia (Engl Ed). 2024. PMID: 37116693 Free article.
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal E, Fernández-Velasco JI, García-Sánchez MI, Sainz de la Maza S, Llufriu S, Álvarez-Lafuente R, Casanova B, Comabella M, Ramió-Torrentà L, Martínez-Rodríguez JE, Brieva L, Saiz A, Eichau S, Cabrera-Maqueda JM, Villarrubia N, Espiño M, Pérez-Miralles F, Montalbán X, Tintoré M, Quiroga-Varela A, Domínguez-Mozo MI, Rodríguez-Jorge F, Chico-García JL, Lourido D, Álvarez-Cermeño JC, Masjuan J, Costa-Frossard L, Villar LM. Monreal E, et al. Among authors: alvarez cermeno jc. JAMA Neurol. 2023 Apr 1;80(4):397-403. doi: 10.1001/jamaneurol.2023.0010. JAMA Neurol. 2023. PMID: 36848127 Free PMC article.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Plata M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X. Meca-Lallana JE, et al. Among authors: alvarez cermeno jc. Neurologia (Engl Ed). 2022 Oct;37(8):615-630. doi: 10.1016/j.nrleng.2019.11.001. Epub 2020 Mar 12. Neurologia (Engl Ed). 2022. PMID: 36195374 Free article.
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Meca-Lallana JE, Oreja-Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió-Torrentà L, Meca-Lallana V, Hernández MA, Marzo ME, Álvarez-Cermeño JC, Rodríguez-Antigüedad A, Montalbán X, Fernández O; Spanish GILENYA Registry Investigators. Meca-Lallana JE, et al. Among authors: alvarez cermeno jc. PLoS One. 2021 Oct 13;16(10):e0258437. doi: 10.1371/journal.pone.0258437. eCollection 2021. PLoS One. 2021. PMID: 34644366 Free PMC article.
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis.
Picón C, Tejeda-Velarde A, Fernández-Velasco JI, Comabella M, Álvarez-Lafuente R, Quintana E, Sainz de la Maza S, Monreal E, Villarrubia N, Álvarez-Cermeño JC, Domínguez-Mozo MI, Ramió-Torrentà L, Rodríguez-Martín E, Roldán E, Aladro Y, Medina S, Espiño M, Masjuan J, Matute-Blanch C, Muñoz-San Martín M, Espejo C, Guaza C, Muriel A, Costa-Frossard L, Villar LM. Picón C, et al. Among authors: alvarez cermeno jc. Front Immunol. 2021 Jul 12;12:685139. doi: 10.3389/fimmu.2021.685139. eCollection 2021. Front Immunol. 2021. PMID: 34322119 Free PMC article.
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome.
Monreal E, Sainz de la Maza S, Costa-Frossard L, Walo-Delgado P, Zamora J, Fernández-Velasco JI, Villarrubia N, Espiño M, Lourido D, Lapuente P, Toboso I, Álvarez-Cermeño JC, Masjuan J, Villar LM. Monreal E, et al. Among authors: alvarez cermeno jc. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5):e1047. doi: 10.1212/NXI.0000000000001047. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34301819 Free PMC article.
174 results